Medtronic plc (MDT) Gains Momentum Through Diabetes and Cardiovascular Operations

robot
Abstract generation in progress

Medtronic plc (MDT) is gaining momentum, particularly in its Diabetes and Cardiovascular operations, which helped offset weaker performance in Neurosciences. Analysts have maintained “Hold” and “Overweight” ratings, with one increasing the price target based on solid third-quarter earnings. The company, a healthcare technology firm specializing in device-based medical therapies for over 70 chronic diseases, delivered modest organic revenue and a slight EPS beat while reaffirming its fiscal year 2026 outlook.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)